<i>HER2</i> and <i>BRAF</i> mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang, Xiangyan; Wu, Jie; Wang, Lili; Zhao, Han; Li, Hong; Duan, Yuhe; Li, Yujun; Xu, Ping; Ran, Wenwen; Xing, Xiaoming

doi:10.7717/peerj.8602

Cited by 15 publications

(20 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HER2 scoring demonstrated high concordance rates between dual-color SISH and CISH methods as the results of the two techniques were almost identical showing 5 out of these 6 cases i.e 5/40 CRCs (12.5%) proved true for HER2 gene amplification. Our results were not far from studies of Valtorta et al, (2015) and Zhang et al, (2020) who reported that 5% and 5.63% of their CRC patients had HER2 amplification. Heppner et al, (2014) and Seo et al, (2014) stated that HER2 amplification ranged from 1.6% to 6.3%.…”

Section: Discussioncontrasting

confidence: 75%

“…An alternative is provided by the use of other in situ hybridization methods such as silver in situ hybridization (SISH) and chromogen in situ hybridization (CISH) which allows the use of an ordinary light microscope and has shown excellent correlation with results obtained using FISH (Abrahão-Machado et al, 2013). As the accurate assessment of HER2 gene amplification status in CRC appears to be particularly important for patients who might undertake this specific targeted therapy (Zhang et al, 2020).…”

Section: Differential Expression Of Her2 and Skp2 In Benign And Maligmentioning

confidence: 99%

See 1 more Smart Citation

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Moussa

Badawy

Helal

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

with younger cases usually complicate polyposis and ulcerative colitis (El-Bolkainy et al., 2013). The outcome of CRC patients has significantly improved over the past decades, reflecting continuous progress in understanding its biology, epidemiology, prevention, early diagnosis and treatment (Siegel et al., 2017), but the identification of clinically actionable oncogenic drivers and related predicted biomarkers are largely elusive (Zhang et al., 2020). CRC is a tumor that develops from the progression of acquired or hereditary premalignant lesions. It arises from interactions among different risk factors (environmental,

show abstract

Section: Discussioncontrasting

confidence: 75%

Section: Differential Expression Of Her2 and Skp2 In Benign And Maligmentioning

confidence: 99%

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Moussa

Badawy

Helal

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Many recent reports have focused on RAS , BRAF (Raf murine sarcoma viral oncogene homolog B) and HER2 (human epidermal growth factor receptor 2 gene) mutations as predictive factors of mCRC patients who receive chemotherapy [ 98 , 99 ]. A study by Zheng investigated the frequency and prognostic role of HER2 and BRAF gene mutations in CRC patients.…”

Section: Future Perspectivesmentioning

confidence: 99%

“…A study by Zheng investigated the frequency and prognostic role of HER2 and BRAF gene mutations in CRC patients. The authors concluded that HER2 amplification significantly correlates with greater bowel wall invasion and a more advanced TNM stage, while HER2 amplification is an independent prognostic factor for worse disease-free survival [ 98 ]. Moreover, a statistically significant correlation for the RAS mutation and overall survival was also proved, whereas RAS mutation and liver metastasis were found to be independent factors for shorter overall survival of CRC patients in multivariate analysis [ 99 ].…”

Section: Future Perspectivesmentioning

confidence: 99%

Circulating Biomarkers of Colorectal Cancer (CRC)—Their Utility in Diagnosis and Prognosis

Łukaszewicz-Zając

2021

JCM

View full text Add to dashboard Cite

The global burden of colorectal cancer (CRC) is expected to increase, with 2.2 million new cases and 1.1 million annual deaths by 2030. Therefore, the establishment of novel biomarkers useful in the early diagnosis of CRC is of utmost importance. A number of publications have documented the significance of the overexpression of several specific proteins, such as inflammatory mediators, in CRC progression. However, little is known about the potential utility of these proteins as circulating blood tumor biomarkers of CRC. Therefore, in the present review we report the results of our previous original studies as well as the findings of other authors who investigated whether inflammatory mediators might be used as novel biomarkers in the diagnosis and prognosis of CRC. Our study revealed that among all of the tested proteins, serum M-CSF, CXCL-8, IL-6 and TIMP-1 have the greatest value in the diagnosis and progression of CRC. Serum TIMP-1 is useful in differentiating between CRC and colorectal adenomas, whereas M-CSF and CRP are independent prognostic factors for the survival of patients with CRC. This review confirms the promising significance of these proteins as circulating biomarkers for CRC. However, due to their non-specific nature, further validation of their sensitivity and specificity is required.

show abstract

“…or single tumor-specific biomarkers (such as carcinoembryonic antigen CEA, carbohydrate antigen-CA199, etc.) [ 5 – 7 ]. To a certain extent, this can provide reference materials for evaluating the prognosis of tumors, however, due to the subjectivity in the collection of pathological data, the complexity and variability of tumor occurrence and development, only reference to clinicopathological data or a single tumor-specific marker cannot make a reliable prediction of tumor prognosis.…”

Section: Introductionmentioning

confidence: 99%

The role of multiple metabolic genes in predicting the overall survival of colorectal cancer: A study based on TCGA and GEO databases

Shi

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

The recent advances in gene chip technology have led to the identification of multiple metabolism-related genes that are closely associated with colorectal cancer (CRC). Nevertheless, none of these genes could accurately diagnose or predict CRC. The prognosis of CRC has been made by previous prognostic models constructed by using multiple genes, however, the predictive function of multi-gene prognostic models using metabolic genes for the CRC prognosis remains unexplored. In this study, we used the TCGA-CRC cohort as the test dataset and the GSE39582 cohort as the experimental dataset. Firstly, we constructed a prognostic model using metabolic genes from the TCGA-CRC cohort, which were also associated with CRC prognosis. We analyzed the advantages of the prognostic model in the prognosis of CRC and its regulatory mechanism of the genes associated with the model. Secondly, the outcome of the TCGA-CRC cohort analysis was validated using the GSE39582 cohort. We found that the prognostic model can be employed as an independent prognostic risk factor for estimating the CRC survival rate. Besides, compared with traditional clinical pathology, it can precisely predict CRC prognosis as well. The high-risk group of the prognostic model showed a substantially lower survival rate as compared to the low-risk group. In addition, gene enrichment analysis of metabolic genes showed that genes in the prognostic model are enriched in metabolism and cancer-related pathways, which may explain its underlying mechanism. Our study identified a novel metabolic profile containing 11 genes for prognostic prediction of CRC. The prognostic model may unravel the imbalanced metabolic microenvironment, and it might promote the development of biomarkers for predicting treatment response and streamlining metabolic therapy in CRC.

show abstract

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Cited by 15 publications

References 45 publications

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Circulating Biomarkers of Colorectal Cancer (CRC)—Their Utility in Diagnosis and Prognosis

The role of multiple metabolic genes in predicting the overall survival of colorectal cancer: A study based on TCGA and GEO databases

Contact Info

Product

Resources

About